What is Genomic Valley Biotech Ltd (539206) share price return in the past 10 years?

Data is not available for this company

What is the share price of Genomic Valley Biotech Ltd (539206)?

Company share prices are keep on changing according to the market conditions. The current trading price of Genomic Valley Biotech Ltd (539206) on 04-Jun-2026 16:59:59 at 16:59 is 27.00.

What is the P/E ratio of Genomic Valley Biotech?

The latest standalone P/E ratio of Genomic Valley Biotech as of 04-Jun-2026 is 274.90.

What is the P/B ratio of Genomic Valley Biotech Ltd (539206)?

The latest standalone P/B ratio of Genomic Valley Biotech Ltd (539206) as of 04-Jun-2026 is 2.10.

What is the 52-week high and low of Genomic Valley Biotech Ltd (539206)?

The 52-week high of Genomic Valley Biotech Ltd (539206) is Rs. 54.27 and the 52-week low is Rs. 20.10.

Genomic Valley Biotech Ltd (539206) Share Analysis – Quality, Growth & Valuation Zone & DeciZen Rating

Name: Genomic Valley Biotech Ltd (539206)
Brand: Genomic Valley Biotech

Genomic Valley Biotech Ltd (539206)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 539206 NSE: Agriculture | Small Cap | Genomic Valley Share Price

Genomic Valley Biotech Ltd (539206)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 539206 NSE: Agriculture | Small Cap | Genomic Valley Share Price

Key Metrics

Valuation Multiples

Market Cap

₹8 Cr.

Current Price

₹27

52-Week Low / High

₹20 / 54

TTM EPS

₹0.1

TTM Sales

₹0.3 Cr.

Book Value per Share

₹12.9

P/E Ratio

274.90

Higher than its 5-year historical median

Industry PE

15.5

Price to Book (P/B)

2.10

Lower than its 5-year historical median

Price to Sales (P/S)

30.77

Higher than its 5-year historical median

EV/EBITDA

186.84

Higher than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

9.57%

Outperforms industry median

Return on Capital Employed (ROCE)

11.87%

Outperforms industry median

Return on Assets (ROA)

8.20%

Operating Profit Margin

52.1%

Net Profit Margin

42.19%

Gross Profit Margin

52.6%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

394.12%

Operating Profit Growth (1 Year)

2100%

Net Profit Growth (1 Year)

1700%

Asset Quality

Promoter Holding

46.06%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹1 Cr.

Equity

₹3.1 Cr.

Face Value

₹10

All Time Low / High

₹8.25 / 108.15

Genomic Valley Biotech stock performance

Key Ratios

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Genomic Valley Biotech Ltd a good quality company?

Genomic Valley Biotech Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Genomic Valley Biotech Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Genomic Valley Biotech Ltd vs industry peers?

Genomic Valley Biotech Ltd revenue CAGR is -0.24%, compared to the industry median CAGR of 0.00%, indicating slower growth and losing its market share.

Q.1 Promoter shareholding and pledge status of Genomic Valley Biotech Ltd?

Promoters hold 46.06% of the Genomic Valley Biotech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Genomic Valley Biotech Ltd over the last decade?

Over the last 5 year(s), the stock has delivered a CAGR of 2.48% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	-6%	-1.3%	1.1%	4.1%	6.1%	-5.1%	0.9%	20.4%	0.5%	11.9%	-
Value Creation Index ⓘ	-1.4	-1.1	-0.9	-0.7	-0.6	-1.4	-0.9	0.5	-1.0	-0.2	-
Growth Parameters ⓘ
Sales ⓘ	0.1	0.4	0.6	1	0.9	0.2	0.1	2.7	0.2	0.8	0
Sales YoY Gr.	-	300%	34.1%	67.8%	-14.1%	-75.3%	-66.7%	3,785.7%	-93.8%	394.1%	-
Adj EPS ⓘ	-1.5	-0.1	0.1	0.8	0.9	-1.8	-1	2.7	0.1	1.2	0.1
YoY Gr.	-	NA	NA	985.7%	23.7%	-294.7%	NA	NA	-98.2%	2240%	-
BVPS (₹) ⓘ	14.9	14.7	14.8	15.6	16.5	14.7	9.4	11.6	11.6	12.8	12.9
Adj Net Profit ⓘ	-0.5	-0	0	0.2	0.3	-0.6	-0.3	0.8	0	0.4	0
Cash Flow from Ops. ⓘ	-0.7	0.4	0.9	-1	0.4	1.5	-2.1	-0.8	-0	0	-
Debt/CF from Ops. ⓘ	-1.1	2.2	0.9	-1.4	3.4	1	0	0	0	0	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	25.3%	-0.2%	128.9%	394.1%
Adj EPS ⓘ	NA	4.5%	NA	2240%
BVPSⓘ	-1.7%	-5%	10.7%	10%
Share Price	-	2.7%	9.3%	-43.8%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	-7.8	-0.8	0.5	5	5.8	-11.7	-8.2	26	0.4	9.6	0.8
Op. Profit Mgn % ⓘ	-406.6	-6.5	17.5	42.2	65.4	-65.6	-534.8	32.4	9.3	52.1	17.1
Net Profit Mgn % ⓘ	-410.9	-9.4	3.6	23.6	33.8	-268.7	-429.1	30.6	9.2	42.2	11.3
Debt to Equity ⓘ	0.2	0.2	0.2	0.3	0.3	0.3	0	0	0	0	0
Working Cap Days ⓘ	8,883	2,098	1,382	829	1,132	3,683	8,514	430	9,602	1,862	2,252
Cash Conv. Cycle ⓘ	0	25	32	40	58	193	144	86	1,519	906	1,961

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	0.11	0.44	0.59	0.99	0.85	0.21	0.07	2.72	0.17	0.84
Operating Expenses ⓘ +	0.55	0.54	0.49	0.57	0.29	0.34	0.45	1.84	0.15	0.40
Manufacturing Costs	0.13	0.01	0.01	0.11	0.05	0.02	0.07	0.01	0	0
Material Costs	0.07	0.10	0.05	0.05	-0.07	0.08	0	1.58	0	0.20
Employee Cost	0.13	0.25	0.34	0.27	0.18	0.09	0.14	0.15	0.04	0.12
Other Costs ⓘ	0.22	0.19	0.10	0.15	0.13	0.16	0.23	0.10	0.11	0.08
Operating Profit ⓘ	-0.44	-0.10	0.10	0.42	0.55	-0.14	-0.38	0.88	0.02	0.44
Operating Profit Margin (%)	-406.0%	-23.2%	17.0%	42.2%	65.4%	-65.6%	-534.0%	32.4%	9.3%	52.1%
Other Income ⓘ +	0.16	0.08	0.01	0.01	0.01	0	0.08	0.04	0	0
Exceptional Items ⓘ	0	0	0.02	0	0	0	0.42	-0.26	0	0
Interest ⓘ	0.02	0	0	0	0.18	0.18	0.04	0	0	0
Depreciation ⓘ	0.05	0.04	0.08	0.19	0.18	0.19	0.08	0.01	0	0
Profit Before Tax ⓘ	-0.34	-0.07	0.06	0.23	0.21	-0.50	-0	0.65	0.02	0.44
Tax ⓘ	-0.01	-0	0.02	0	-0.08	0.06	0.01	0	-0	0.09
Profit After Tax	-0.33	-0.07	0.03	0.23	0.29	-0.56	-0.01	0.65	0.02	0.36
PAT Margin (%)	-307.0%	-15.5%	5.7%	23.6%	33.8%	-268.0%	-13.2%	23.8%	9.2%	42.2%
Adjusted EPS (₹)	-1.1	-0.2	0.1	0.8	0.9	-1.8	-0.0	2.1	0.1	1.2
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Genomic Valley - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	5.58	4.49	4.53	4.76	5.05	4.49	2.88	3.53	3.54	3.90
Share Capital ⓘ	3.05	3.05	3.05	3.05	3.05	3.05	3.05	3.05	3.05	3.05
Reserves ⓘ	2.53	1.44	1.47	1.71	1.99	1.43	-0.18	0.47	0.49	0.84
Debt +	0.75	0.75	0.75	1.48	1.48	1.55	0	0	0	0
Long Term Debt	0.75	0.75	0.75	1.48	1.48	1.55	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	0	0.01	0.01	0	0.06	0.04	0	0.61	0.60	0.01
Others Liabilities ⓘ	0.72	0.76	1.39	0.93	1.35	1.54	0.92	0.28	0.19	0.45
Total Liabilities ⓘ	7.06	6.02	6.67	7.18	7.94	7.61	3.80	4.42	4.33	4.36
Fixed Assets
Net Fixed Assets ⓘ +	3.18	3.63	4.12	4.31	4.47	5.86	1.75	0	0	0.01
Gross Block	3.25	3.75	4.32	4.70	5.02	6.60	2.57	0.48	0	0.01
Accumulated Depreciation	0.08	0.12	0.20	0.39	0.55	0.74	0.82	0.48	0	0
CWIP ⓘ	0	0	0.38	0.49	0.49	0.49	0	0	0	0
Investments ⓘ	0.11	0	0	0	0	0	0	0	0.02	0
Inventories	0	0.07	0.03	0.12	0.12	0	0	0	0	0.28
Trade Receivables	0	0	0.02	0.06	0.10	0.06	0	2.22	2.53	2.21
Cash Equivalents	0.01	0.05	0.01	0.08	0.04	0.01	0	0.04	0.01	0.05
Others Assets ⓘ	3.76	2.26	2.11	2.13	2.72	1.19	2.04	2.16	1.78	1.80
Total Assets ⓘ	7.06	6.02	6.67	7.18	7.94	7.61	3.80	4.42	4.33	4.36

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-0.69	0.35	0.87	-1.04	0.44	1.48	-2.13	-0.78	-0.02	0.03
PBT ⓘ	-0.34	-0.07	0.06	0.23	0.21	-0.50	-0.42	0.91	0.02	0.44
Adjustment ⓘ	-0.11	-0.03	0.04	0.18	0.18	0.19	-0.26	-0.03	-0	-0
Changes in Working Capital ⓘ	-0.23	0.45	0.77	-1.45	0.06	1.8	-1.45	-1.66	-0.03	-0.33
Tax Paid ⓘ	0	0	0	0	0	0	0	0	0	-0.09
Cash Flow From Investing Activity ⓘ +	0.53	-0.31	-0.91	0.37	-0.47	-1.58	3.67	1.52	-0.02	0.01
Capex	-0.08	-0.50	0	0.36	-0.48	-1.58	0	1.48	0	-0.01
Net Investments	0.44	0.11	-0.94	0	0	0	5.35	0	-0.02	0.02
Others ⓘ	0.16	0.08	0.03	0.01	0	-0	-1.68	0.04	0	0
Cash Flow From Financing Activity ⓘ +	0	0	0	0.73	0	0.07	-1.55	-0.70	0	0
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0.73	0	0.07	-1.55	-0.70	0	0
Net Cash Flow ⓘ	-0.16	0.04	-0.04	0.06	-0.04	-0.03	-0.01	0.04	-0.04	0.04

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	-7.08	-1.51	0.76	5.01	5.83	-11.73	-0.25	20.24	0.43	9.57
ROCE (%)	-5.99	-1.31	1.12	4.12	6.1	-5.14	0.93	20.35	0.45	11.87
Asset Turnover Ratio	0.02	0.07	0.09	0.14	0.11	0.03	0.01	0.66	0.04	0.19
PAT to CFO Conversion(x)	N/A	N/A	29	-4.52	1.52	N/A	N/A	-1.2	-1	0.08
Working Capital Days
Receivable Days	0	0	14.30	15.10	34.70	147	0	297.30	5,248.70	1,026
Inventory Days	0	58.50	31.90	28.20	52.30	0	0	0	0	122.90
Payable Days	0	18.70	70.50	44.50	-183	231.40	3,716	70.40	0	554.30

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Genomic Valley Biotech Ltd FAQs

The current trading price of Genomic Valley on 04-Jun-2026 16:59 is ₹27.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Genomic Valley stood at ₹8.25 Cr

The latest P/E ratio of Genomic Valley as of 03-Jun-2026 is 274.9.

The latest P/B ratio of Genomic Valley as of 03-Jun-2026 is 2.10.

The 52-week high of Genomic Valley is ₹54.27 and the 52-week low is ₹20.10.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Genomic Valley is ₹0.27 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Genomic Valley Biotech Ltd is a below average quality company.

The key valuation ratios of Genomic Valley Biotech Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Genomic Valley Biotech Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Genomic Valley Biotech Ltd

Genomic Valley Biotech Limited (GVBL) is formed with the objective of conducting research in the field of Biotechnology (Plant & Animal) and also to undertake commercial production of Plant Tissue Cultured Plants of different species to feed the genetically improved plant market nationally as well as internationally.

Currently, the company is engaged in providing consultancy in: a. High-Tech Cultivation through Environment Controlled Poly Houses, NFT & DFT etc; and b. Organic Farming --- Open Field Cultivation using Bio-Fertilizer. The company is also trading in agricultural and horticultural products.

Business area of the company

The Company is providing consultancy in the Horticultural and Agricultural products. The company is also trading in Horticultural and Agricultural products.

Genomic Valley Biotech Ltd (539206)

Genomic Valley Biotech Ltd (539206)

Genomic Valley Biotech stock performance

Check Before You Invest

M-Cap below 100cr DeciZen not available

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Genomic Valley - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Genomic Valley Biotech Ltd FAQs

About Genomic Valley Biotech Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Genomic Valley Biotech Ltd (539206)

Genomic Valley Biotech Ltd (539206)

Genomic Valley Biotech stock performance

Check Before You Invest

M-Cap below 100cr DeciZen not available

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Genomic Valley - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Genomic Valley Biotech Ltd FAQs

What is the share price of Genomic Valley?

What is the market cap of Genomic Valley?

What is the P/E ratio of Genomic Valley?

What is the P/B ratio of Genomic Valley?

What is the 52-week high and low of Genomic Valley?

What is the TTM revenue of Genomic Valley?

Is Genomic Valley Biotech Ltd a good quality company?

Is Genomic Valley Biotech Ltd undervalued or overvalued?

Is Genomic Valley Biotech Ltd a good buy now?

About Genomic Valley Biotech Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.